The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomized, double- blind, placebo-controlled phase 2 study

Park J1, Song M1, Kim J H2, Han J3, Lee J Z4, Oh S5, Seo J T6, Choi J B7, Park S8, Kim K S1, Park W H9, Choo M1

Abstract Category

Pharmacology

Abstract 564
Pharmacology
Scientific Open Discussion Poster Session 37
Thursday 23rd October 2014
13:30 - 14:30
Poster Area
Overactive Bladder Clinical Trial Constipation Pharmacology Prospective Study
1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine,Seoul, Korea, 2. Department of Urology, Severance Hospital, Yonsei University College of Medicine,Seoul, Korea, 3. Department of Urology, Pusan National University Yangsan Hospital, Pusan, 4. Department of Urology, Pusan National University Hospital, Busan, Korea, 5. Department of Urology, Seoul National University Hospital, Seoul, Korea, 6. Department of Urology, Cheil General Hospital & Women's Helathcare Center, Kwandong University College of Medicine, Seoul, Korea,, 7. Department of Urology, Ajou University Hospital, Suwon, Korea, 8. Department of Urology, Ulsan university hospital, Ulsan, Korea, 9. 9Department of Urology, Inha University College of Medicine, Incheon, Korea
Links

Abstract

28/03/2024 18:45:58